Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
69.92
-3.81 (-5.16%)
Streaming Delayed Price
Updated: 10:59 AM EST, Nov 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
3
4
5
Next >
Don’t Confuse Brains With A Bull Market, Or Price With Value
November 10, 2024
If you are interested in the stock market, maybe it is time to stop focusing on The Fed.
Via
Talk Markets
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
November 07, 2024
From
GeneDx
Via
Business Wire
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
November 04, 2024
From
GeneDx
Via
Business Wire
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
November 03, 2024
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).
Via
Benzinga
The Analyst Verdict: GeneDx Hldgs In The Eyes Of 6 Experts
October 16, 2024
Via
Benzinga
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
September 19, 2024
The company provides sequencing tools to help diagnose children with rare diseases.
Via
Investor's Business Daily
Gold Gains 1%; Phillips 66 Shares Fall After Q3 Results
October 29, 2024
Via
Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
October 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 29, 2024
Via
Benzinga
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
October 29, 2024
GeneDx stock rises as Q3 results beat expectations with EPS loss improvement, 44% revenue growth to $76.87M, and 77% increase in test revenue.
Via
Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
October 29, 2024
Via
Benzinga
Expert Ratings For GeneDx Hldgs
July 17, 2024
Via
Benzinga
The Latest Analyst Ratings For GeneDx Hldgs
June 26, 2024
Via
Benzinga
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
October 29, 2024
From
GeneDx
Via
Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
October 24, 2024
From
GeneDx
Via
Business Wire
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
October 08, 2024
From
GeneDx
Via
Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 03, 2024
From
GeneDx
Via
Business Wire
The Markets Are Ignoring Risk, But That Does Not Mean You Should...
September 29, 2024
It is Fall clean-up time. Sell lagging and sagging companies.
Via
Talk Markets
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 27, 2024
From
GeneDx
Via
Business Wire
GeneDx to Participate in Fall Investor Conferences
August 12, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
GeneDx
Via
Business Wire
WGS Stock Earnings: GeneDx Hldgs Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
WGS stock results show that GeneDx Hldgs beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
July 18, 2024
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins.
Via
Benzinga
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
July 11, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
7 Small-Cap Stocks With Massive Potential Returns
July 06, 2024
Explore these small-cap stocks with high potential in health care, REITs, entertainment, hardware, finance, and distribution industries.
Via
InvestorPlace
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
June 10, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying
June 06, 2024
Via
Benzinga
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
June 05, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.